PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
Abstract Background The MET receptor tyrosine kinase represents a promising target in cancer. PIK3CA activating mutations are common in several tumor types and can potentially confer resistance to anti-receptor tyrosine kinase therapy. Methods MET and/or PI3K pathway inhibition was assessed in NIH3T...
Main Authors: | Lluís Nisa, Pascal Häfliger, Michaela Poliaková, Roland Giger, Paola Francica, Daniel Matthias Aebersold, Roch-Philippe Charles, Yitzhak Zimmer, Michaela Medová |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12943-017-0660-5 |
Similar Items
-
The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects
by: Michaela Medová, et al.
Published: (2013-12-01) -
Functional role of SGK3 in PI3K/Pten driven liver tumor development
by: Hui Cao, et al.
Published: (2019-04-01) -
The Role of PI3K in Met Driven Cancer: A Recap
by: Alexia Hervieu, et al.
Published: (2018-10-01) -
Deciphering MET‐dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics
by: Ariel Bensimon, et al.
Published: (2020-06-01) -
Clinical profile of overgrowth syndromes consistent with PROS (PIK3CA-related overgrowth syndromes)—A case series
by: Lydia Mathew, et al.
Published: (2020-01-01)